Eli Lilly is significantly scaling back its planned multi-billion-euro investment in Alzey, Rhineland-Palatinate. The US pharmaceutical company is responding to the German government’s healthcare cost-cutting plans. A large plant for producing weight-loss injections and diabetes medication was originally slated for the site; instead of 2.3 billion euros, only about half that amount will now be invested. However, the facility is still scheduled to launch in 2027, albeit with reduced capacity. As a result, the number of planned jobs will decrease, while the project’s industrial significance for Germany diminishes. (handelsblatt: 03.06.26)
Eli Lilly scales back expansion plans due to new cost-cutting measures
The move is prompted by the planned Statutory Health Insurance Contribution Rate Stabilization Act proposed by Health Minister Nina Warken. While intended to relieve the financial burden on health insurance funds, the legislation entails higher rebates for pharmaceutical manufacturers. Additionally, new reimbursement rules are altering pricing structures for patent-protected drugs.
CEO Dave Ricks described the plans as a “terrible signal.” Consequently, the company intends to complete only the “minimum scope of the high-tech production site in Alzey” for the time being. Further expansion phases now depend on whether Germany offers a more reliable regulatory environment again.
Alzey to get plant, but with reduced capacity
The structural shell of the Alzey facility is nearly complete, and interior fit-out work is already underway. According to current figures, Lilly has hired around 300 employees.
In addition, approximately 2,500 people are working at the construction site through service providers and project partners. Originally, the project was expected to create jobs for up to 1,000 skilled workers in Alzey; however, that target is no longer in effect.
Boehringer also cuts planned investments
The impact is not limited to a single location. At the same time, Boehringer Ingelheim halted planned investments totaling 900 million euros in Germany. The company also cites the federal government’s austerity policies as the reason.
This development is therefore of particular significance for Rhineland-Palatinate. Lilly is building in Alzey, while Boehringer has its headquarters in Ingelheim. Moreover, the pharmaceutical and chemical industries drive a large share of the region’s economic output.
Federal Government Plans to Ease Burden on Health Insurance Funds
The federal government is nonetheless sticking to its course. It intends to relieve statutory health insurance funds of €16.3 billion in costs in 2027, aiming to curb rising supplementary premiums.
However, companies view the consequences much more critically. Higher manufacturer rebates and stricter reimbursement rules reduce certainty for financial planning. Consequently, Eli Lilly is considering whether to direct future capital investment toward locations such as Pennsylvania, the UK, or Canada instead.